Collegium Pharmaceutical ... (COLL)
NASDAQ: COLL
· Real-Time Price · USD
29.82
-0.41 (-1.36%)
At close: May 19, 2025, 3:59 PM
29.83
0.03%
After-hours: May 19, 2025, 04:30 PM EDT
Company Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.
Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical Inc.
| Country | United States |
| IPO Date | May 7, 2015 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 357 |
| CEO | Vikram Karnani |
Contact Details
Address: 100 Technology Center Drive Stoughton, Massachusetts United States | |
| Website | https://www.collegiumpharma.com |
Stock Details
| Ticker Symbol | COLL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001267565 |
| CUSIP Number | 19459J104 |
| ISIN Number | US19459J1043 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vikram Karnani | Chief Executive Officer, President, Executive Vice President & Director |
| Colleen Tupper | Executive Vice President & Chief Financial Officer |
| Dean J. Patras | Chief People Officer |
| David Dieter | Executive Vice President, General Counsel & Corporate Secretary |
| Dr. Thomas B. Smith FAAFP, M.D. | Executive Vice President & Chief Medical Officer |
| Jane Gonnerman | Executive Vice President of Strategy & Corporate Development |
| Michael Thomas Heffernan B.S. Pharm, R.Ph. | Co-Founder & Chairman |
| Scott Dreyer | Executive Vice President & Chief Commercial Officer |
| Scott Sudduth | Head of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 12, 2025 | 8-K | Current Report |
| May 08, 2025 | 10-Q | Quarterly Report |
| May 08, 2025 | 8-K | Current Report |
| May 02, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 02, 2025 | SCHEDULE 13G | Filing |
| Apr 28, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Mar 28, 2025 | DEFA14A | Filing |
| Mar 28, 2025 | ARS | Filing |
| Mar 28, 2025 | DEF 14A | Filing |